DCDC2C inhibitors refer to a class of compounds designed to inhibit the activity of the DCDC2C protein, which is a member of the doublecortin domain-containing protein family. DCDC2C, like other members of this family, plays a role in the regulation of microtubule dynamics, a crucial aspect of cytoskeletal organization and intracellular transport. The doublecortin (DC) domain, found in DCDC2C, is known for its ability to bind to and stabilize microtubules, thereby influencing cellular processes such as mitosis, migration, and structural maintenance. DCDC2C is involved in maintaining the integrity of these structures and may also participate in intracellular signaling pathways that rely on proper cytoskeletal arrangement.
Inhibitors of DCDC2C are designed to disrupt its interaction with microtubules, potentially destabilizing microtubule formation or hindering the regulatory functions that DCDC2C exerts on these structures. These inhibitors can vary widely in their chemical composition but are typically crafted to target the DC domain of DCDC2C or other key regions critical for its activity. By inhibiting DCDC2C, these compounds may alter cellular dynamics that depend on the microtubule cytoskeleton, such as intracellular trafficking, cell division, and structural support. Understanding the structure of DCDC2C and its specific role within the microtubule network is essential in designing inhibitors that can selectively and effectively block its function. This class of inhibitors offers valuable tools for studying the underlying mechanisms of cellular organization and the molecular pathways that rely on cytoskeletal interactions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that can affect phosphorylation states, potentially altering DCDC2C activity if it is regulated by phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that can disrupt downstream signaling, potentially affecting DCDC2C if it's part of the PI3K/AKT pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
An inhibitor of MEK, which might impact DCDC2C function if it's involved in the MAPK/ERK pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR signaling and could alter DCDC2C activity if mTOR signaling regulates DCDC2C. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Inhibits protein synthesis, which could reduce DCDC2C levels if it has a rapid turnover rate. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that could increase DCDC2C levels by preventing its degradation, indirectly affecting its activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Another proteasome inhibitor that could stabilize DCDC2C levels and affect its cellular functions. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An ERK inhibitor that might suppress DCDC2C activity if it's modulated by the ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that could influence DCDC2C function if p38 MAPK is part of its regulatory mechanism. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which may affect DCDC2C if it is involved in the JNK signaling pathway. | ||||||